\n\nMethods/design: The prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III ADAPT trial has an innovative “umbrella” protocol design. The “umbrella” is common for all patients, consisting of dynamic testing of early therapy response. ADAPT will recruit 4,936 patients according to their respective breast cancer subtype in four distinct sub-trials at 80 trial sites in Germany; 4,000 patients with hormone receptor positive (HR+) and HER2 negative disease will be included

in the ADAPT HR+/HER2-sub-trial, where treatment decision is based on risk assessment and therapy response to induction therapy, and 380 patients will be included in ADAPT HER2+/HR+. A further 220 patients will be included in ADAPT HER2+/HR- and 336 patients will be recruited for ADAPT Triple Negative. These three sub-trials focus on JNJ-26481585 concentration identification of early surrogate markers for therapy success in the neoadjuvant setting. Patients will be allocated to the respective sub-trial according to the result of their diagnostic core biopsy, as reported by local/central pathology for HR and HER2 status.\n\nDiscussion: Recent trials, such as the GeparTrio, have shown that response-guided therapy using clinical response may improve outcome. For chemotherapy or HER2-targeted treatment, pathologic complete response in a neoadjuvant setting is an excellent predictor

of outcome. For endocrine therapy, response to short induction treatment – as defined by decrease in tumor cell proliferation – strongly correlates with outcome. ADAPT now aims to combine static prognostic and dynamic predictive markers, focusing selleck not Selleckchem Epigenetic inhibitor just on single therapeutic targets, but also on general markers of proliferation

and cell death. Biomarker analysis will help to optimize selection of subtype-specific treatment.\n\nTrial registration: ClinicalTrials.gov: ADAPT Umbrella: NCT01781338; ADAPT HR+/HER2-: NCT01779206; ADAPT HER2+/HR+: NCT01745965; ADAPT HER2+/HR-: NCT01817452; ADAPT TN: NCT01815242.”
“A community based study was conducted with women employees in a private sector office of Delhi. A total of 106 women who volunteered to participate in the study were trained in the technique of breast self-examination (BSE) with the help of a lecture, video, demonstration of the technique on breast model by the investigator followed by feedback demonstration by the technique participants. Susequently, short text meassges (SMS) were sent according to the last menstrual period (LMP) information collected. Women who did not menstruate were sent reminders on the first of every month. Statistical analysis was done using epinfo software. All the 106 participants owned a personal mobile number, while 89% had a private connection of cell phone and 11% had a connection provided by a government agency. Some 76 (71.7%) of the women had a regular menstrual period, 11 (10.